Asset
BALSTILIMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05033132 | phase2 | withdrawn | 2021-10-01 | 2024-12-30 | Agenus Inc. | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
| NCT04156100 | phase1 | terminated | 2019-12-10 | 2021-04-08 | Agenus Inc. | A Study in Subjects With Advanced Solid Tumors |
| NCT03104699 | phase1_2 | completed | 2017-04-11 | 2022-06-15 | Agenus Inc. | A Study of AGEN2034 in Advanced Tumors and Cervical Cancer |
| NCT05529316 | phase2 | active_not_recruiting | 2022-12-12 | 2028-02-01 | Agenus Inc. | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma |
| NCT05608044 | phase2 | active_not_recruiting | 2022-11-30 | 2027-09-01 | Agenus Inc. | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer |
FDA applications (0)
This company has no applications containing this asset.